Search research articles
Contact Us
Filters
Showing results (81-90 of 102) with videos related to
Page
of 11
Sort By:
Blood
|
November 17, 2021
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
Swagata Goswami, Rajeswaran Mani, Jessica Nunes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
Leo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 11, 2015
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)
Yvonne A Efebera, Susan Geyer, Leslie Andritsos, et al.
Journal of Hematology & Oncology
|
March 18, 2025
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Elvira Umyarova, Charles Pei, William Pellegrino, et al.
Transplantation and Cellular Therapy
|
January 17, 2026
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trial
Joseph Pidala, Brent Logan, Stephanie J Lee, et al.
Transplantation and Cellular Therapy
|
November 10, 2025
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial
Jason G Dehn, Brent Logan, Stephanie J Lee, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 7, 2024
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial
Jason G Dehn, Brent Logan, Bronwen E Shaw, et al.
Blood Advances
|
June 9, 2026
Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial
Asad Bashey, Brent R Logan, LaQuisa C Hill, et al.
Research Square
|
February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22
Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Blood Advances
|
October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy
Scott R Solomon, Andrew St Martin, Nirav N Shah, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 102) with videos related to
Sort By:
Page
of 11
Blood
|
November 17, 2021
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
Swagata Goswami, Rajeswaran Mani, Jessica Nunes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
Leo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 11, 2015
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)
Yvonne A Efebera, Susan Geyer, Leslie Andritsos, et al.
Journal of Hematology & Oncology
|
March 18, 2025
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Elvira Umyarova, Charles Pei, William Pellegrino, et al.
Transplantation and Cellular Therapy
|
January 17, 2026
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trial
Joseph Pidala, Brent Logan, Stephanie J Lee, et al.
Transplantation and Cellular Therapy
|
November 10, 2025
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial
Jason G Dehn, Brent Logan, Stephanie J Lee, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 7, 2024
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial
Jason G Dehn, Brent Logan, Bronwen E Shaw, et al.
Blood Advances
|
June 9, 2026
Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial
Asad Bashey, Brent R Logan, LaQuisa C Hill, et al.
Research Square
|
February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22
Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Blood Advances
|
October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy
Scott R Solomon, Andrew St Martin, Nirav N Shah, et al.
Page
of 11